Phase 1 Study of Coronary Heart Disease Proteomics Research
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Heart Disease
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Differential Proteins and the levels of Differential Proteins
- Last Updated
- 12 years ago
Overview
Brief Summary
The protein composition of HDL is complicated. The investigators have identified 40 distinct proteins associated with HDL by proteomics technology, and these proteins have been confirmed to be related to the function of anti-inflammation, anti-oxidation, improvement of endothelial function, inhibition of thrombosis and so on. And the investigators also found that the levels of some proteins in HDL changed in patients with coronary heart disease, compared with the healthy control group.
So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.
Investigators
Yan Li-rong
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs
Chinese Academy of Medical Sciences, Fuwai Hospital
Eligibility Criteria
Inclusion Criteria
- •Angiographic evidence of coronary artery disease, and no lipid-lowering therapy in the past 2 weeks for treatment group;
Exclusion Criteria
- •Use of potent lipid-lowering therapy for more than 2 weeks; myocardial infarction or percutaneous coronary intervention in the past 6 months; severe congestive heart failure, valvular heart disease and other non-coronary heart disease cardiovascular disease; liver or renal dysfunction; connective tissue disease; infection, Malignancy; and other conditions that physicians considered inappropriate to the study.
Outcomes
Primary Outcomes
Differential Proteins and the levels of Differential Proteins
Time Frame: up to 3 years